Related Experiment Videos
Genetics and pharmacogenetics in heart failure.
Eric M Snyder1, Thomas P Olson, Bruce D Johnson
1Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. snyder.eric@mayo.edu
Current Heart Failure Reports
|September 22, 2007
Summary
Genetic factors significantly influence heart failure development and treatment response. Understanding these genetic variations can personalize pharmacologic interventions for better patient outcomes in heart failure.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Heart failure (HF) is a complex, heterogeneous disease influenced by genetic and environmental factors.
- While some HF forms are clearly heritable, the genetic role in classic HF pathogenesis requires further elucidation.
- Modifier genes impact HF patient exercise capacity, organ function, and survival.
Purpose of the Study:
- To review the role of genetic variations in heart failure.
- To explore the influence of modifier genes on HF pathophysiology and treatment.
- To highlight the impact of genetics on pharmacologic intervention in HF.
Main Methods:
- Literature review focusing on genetic modifiers in heart failure.
- Analysis of studies investigating gene-environment interactions in HF.
- Examination of genetic influences on adrenergic, renin-angiotensin-aldosterone, and vascular systems in HF.
Main Results:
- Genetic variations play a crucial role in HF development and progression.
- Specific genes modulate exercise capacity, cardiovascular function, and survival in HF patients.
- Genetic factors influence individual responses to heart failure pharmacotherapies.
Conclusions:
- Genetics significantly impacts heart failure heterogeneity and progression.
- Identifying genetic profiles can optimize pharmacologic treatments for heart failure.
- Personalized medicine approaches in heart failure require understanding genetic determinants.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...